Buprenorphine Market, By Application, By Route of Administration, By Distribution Channel, By Geography

PUBLISHED: March 25, 2025

PAGES: 180 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Buprenorphine Market is estimated to be valued at USD 7.28 Bn in 2025 and is expected to reach USD 19.25 Bn by 2032, growing at a compound annual growth rate (CAGR) of 14.9% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 7.28 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	14.90%	2032 Value Projection:	USD 19.25 Bn

Buprenorphine is the first medication to treat opioid use disorder that may be prescribed or distributed in doctor's offices, vastly expanding access to care. Buprenorphine should be prescribed as a component of a thorough treatment plan that includes counseling and other services to give patients a whole-person approach, as is the case with all drugs used in therapy. Buprenorphine provides a number of benefits for those with opioid use disorder and for those for whom therapy at an opioid treatment center is uncomfortable or inappropriate.

The following buprenorphine products are approved for the treatment of opioid use disorder by the U.S. FDA:

Generic buprenorphine/naloxone sublingual tablets
Buprenorphine sublingual tablets (Subutex)
Buprenorphine/naloxone sublingual films (Suboxone)
Buprenorphine/naloxone sublingual tablets (Zubsolv)
Buprenorphine/naloxone buccal film (Bunavail)
Buprenorphine implants (Probuphine)
Buprenorphine extended-release injection (Sublocade)

Market Dynamics

Increasing approval of buprenorphine by regulatory authorities for subcutaneous use is expected to increase the global buprenorphine market over the forecast period. For instance, in March, 2018, Indivior PLC, a pharmaceutical company, announced that SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use (CIII), is available in the U.S. The U.S. Food and Drug Administration (FDA) has granted approval for the use of SUBLOCADE for the treatment of moderate to severe opioid use disorder (OUD) in adult patients who have started therapy with a transmucosal buprenorphine-containing medication and have undergone dose titration for at least seven days. It should only be given by medical professionals, and it should be part of a comprehensive treatment plan that also includes counseling and psychosocial support.

Key features of the study:

This report provides in-depth analysis of the global buprenorphine market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global buprenorphine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are Mallinckrodt, Noramco, Unichem Laboratories Ltd., Sanofi, Johnson Matthey, Arevipharma Gmbh, Resonance Laboratories Pvt. Ltd., Sun Pharmaceutical Industries Limited, Rusan Pharma Ltd. Micro Orgo Chem, Faran Shimi Pharmaceutical, Indivior PLC, Titan Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC.
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global buprenorphine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global buprenorphine market

Detailed Segmentation:

By Application:
- Analgesic
- Opioid Antagonist
By Route of Administration:
- Injectables
- Sublingual
- Transdermal
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Mallinckrodt
- Noramco
- Unichem Laboratories Ltd.
- Sanofi
- Johnson Matthey
- Arevipharma Gmbh
- Resonance Laboratories Pvt. Ltd.
- Sun Pharmaceutical Industries Limited
- Rusan Pharma Ltd.
- Micro Orgo Chem
- Faran Shimi Pharmaceutical
- Indivior PLC
- Titan Pharmaceuticals, Inc.
- Hikma Pharmaceuticals PLC.

Product Code: CMI4237

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Application
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Key Highlights
Product Launch
Technological Advancements
PEST Analysis
Regulatory Scenario
Mergers and Acquisitions

4. Global Buprenorphine Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Buprenorphine Market, By Application, 2020-2032, (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Analgesic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Opioid Antagonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

6. Global Buprenorphine Market, By Route of Administration, 2020-2032, (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Injectables
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Sublingual
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

7. Global Buprenorphine Market, By Distribution Channel, 2020-2032, (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segments Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

8. Global Buprenorphine Market, By Region, 2020-2032, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Billion)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Mallinckrodt
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Noramco
Unichem Laboratories Ltd.
Sanofi
Johnson Matthey
Arevipharma Gmbh
Resonance Laboratories Pvt. Ltd.
Sun Pharmaceutical Industries Limited
Rusan Pharma Ltd.
Micro Orgo Chem
Faran Shimi Pharmaceutical
Indivior PLC
Titan Pharmaceuticals, Inc.
Hikma Pharmaceuticals PLC.